# Charles River Raises 2026 Non-GAAP EPS Outlook to $11.35-$11.55

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/49461
Published: 2026-11-05T17:48:30.000Z
Updated: 2026-11-05T17:48:30.000Z
Section: Business

> The company also lifted its organic revenue-growth forecast to at least 1.5% and expects about 150 basis points of sequential margin improvement in the fourth quarter.

Charles River Laboratories International, Inc. raised its 2026 non-GAAP earnings-per-share outlook to $11.35-$11.55 after third-quarter non-GAAP EPS came in above its prior outlook, while lifting its organic revenue-growth forecast to at least 1.5%.

Third-quarter non-GAAP EPS was $3.09.

Higher operating income and a lower tax rate contributed to the increase.

The DSA book-to-bill ratio was 1.09x for a fourth consecutive quarter above 1x. Charles River’s long-term target is 5% to 7% DSA organic revenue growth. The company expects gradual DSA growth, while noting that pricing power has not returned and that study timing, mix and resource availability affect visibility.

CEO Birgit Girshick described the quarter as showing “continued momentum in the improving biopharmaceutical demand environment.”

For the fourth quarter, Charles River expects about 150 basis points of sequential non-GAAP operating-margin improvement.

The Create the Future program targets more than $300 million in savings.